Please login to the form below

Not currently logged in
Email:
Password:

Licensing deals

This page shows the latest Licensing deals news and features for those working in and with pharma, biotech and healthcare.

Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’

Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’

In June, Merck completed the spin-off of women’s health company Organon, freeing up approximately $9bn for new deals and collaborations. ... Executing value-enhancing business development is a top priority, and we intend to add to our pipeline through

Latest news

More from news
Approximately 2 fully matching, plus 87 partially matching documents found.

Latest Intelligence

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    the pipeline, the use of technology in medicine is expected to grow and so are the associated deals, mergers and acquisitions. ... They also can help identify collaboration opportunities including partnerships, licensing deals and merger or acquisition

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    returns. That includes an exit from areas like neurology – which predates Bourla’s appointment as CEO but was set up while he was COO – and a series of bolt-on deals ... Meanwhile, Galapagos looks set to continue adding to its pipeline through

  • A market-adapted agile approach to launch excellence A market-adapted agile approach to launch excellence

    Furthermore, increases. in region or market-specific licensing deals for launch products have led companies to devolve to region-specific cross-functional teams for tailored launch preparation, allowing different thinking to

  • The changing nature of approvals – what does the future hold? The changing nature of approvals – what does the future hold?

    Mega-mergers are also becoming less frequent; instead, we’re seeing fewer but larger deals. ... Based on CMR International data, since 2015 we have seen the number of drug commercialisation/licensing deals continue to gradually decline while the

  • Deal Watch October 2018

    Licensing &. research. collaboration. $550m. Novartis/. Mylan. TOBI Podhaler and TOBI solution for cystic fibrosis. ... Licensing &. collaboration. $40m. All deals are for worldwide rights unless stated otherwise:.

More from intelligence
Approximately 0 fully matching, plus 33 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
Guide
How to embrace behavioural science principles in healthcare MR...